Abstract
Amyloid beta peptide (Aβ) is implicated in the pathogenesis of Alzheimers disease (AD), particularly as oligomers or polymers that are correlated with Ab cellular toxicity. Inhibition of the formation of toxic forms of Aβ has therefore emerged as one approach to the treatment of AD. This article reviews efforts to adapt the structure of Aβ to the design and testing of peptide-based inhibitors of Aβ polymerization of interest as potential AD therapeutics.
Keywords: Peptide Inhibitors, Beta Amyloid Aggregation, Amyloid beta peptide
Current Topics in Medicinal Chemistry
Title: Peptide Inhibitors of Beta Amyloid Aggregation
Volume: 2 Issue: 4
Author(s): Mark A. Findeis
Affiliation:
Keywords: Peptide Inhibitors, Beta Amyloid Aggregation, Amyloid beta peptide
Abstract: Amyloid beta peptide (Aβ) is implicated in the pathogenesis of Alzheimers disease (AD), particularly as oligomers or polymers that are correlated with Ab cellular toxicity. Inhibition of the formation of toxic forms of Aβ has therefore emerged as one approach to the treatment of AD. This article reviews efforts to adapt the structure of Aβ to the design and testing of peptide-based inhibitors of Aβ polymerization of interest as potential AD therapeutics.
Export Options
About this article
Cite this article as:
Findeis A. Mark, Peptide Inhibitors of Beta Amyloid Aggregation, Current Topics in Medicinal Chemistry 2002; 2 (4) . https://dx.doi.org/10.2174/1568026024607508
DOI https://dx.doi.org/10.2174/1568026024607508 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Regulation of Self-Reactive T Cells by Human Immunoglobulins- Implications for Multiple Sclerosis Therapy
Current Pharmaceutical Design May Endocrine Therapy be Associated with Cognitive Impairment in Breast Cancer Patients?
Clinical Cancer Drugs What About Drug Checking? Systematic Review and Netnographic Analysis of Social Media
Current Neuropharmacology Experimental Drugs for Neuropathic Pain
Current Neuropharmacology Meningioma in an Elderly Presenting as Psychosis: A Case Report
Clinical Cancer Drugs The Role of Endoproteolytic Processing in Neurodegeneration
CNS & Neurological Disorders - Drug Targets In Silico Evaluation of Acetylation Mimics in the 27 Lysine Residues of Human Tau Protein
Current Alzheimer Research Pharmacokinetic Considerations of Inhaled Pharmaceuticals for Systemic Delivery
Current Pharmaceutical Design Epigenetic Regulation of Epithelial-Mesenchymal Transition by Hypoxia in Cancer: Targets and Therapy
Current Pharmaceutical Design Stem Cells as In Vitro Models of Disease
Current Stem Cell Research & Therapy miRNAs Highlights in Stem and Cancer Cells
Mini-Reviews in Medicinal Chemistry Non-Analgesic Effects of Opioids: The Interaction of Opioids with Bone and Joints
Current Pharmaceutical Design Metformin: A Growing Journey from Glycemic Control to the Treatment of Alzheimer’s Disease and Depression
Current Medicinal Chemistry Drug-Induced Impulse Control Disorders: A Review
Current Clinical Pharmacology A Novel Strategy to Manage Tolerance to Lamotrigine in Bipolar II Depression
Letters in Drug Design & Discovery Synthesis, Experimental and Computational Studies of N-(4-amino-6-oxo- 1,6-dihydropyrimidin-5-yl)benzamide
Letters in Organic Chemistry Small Molecules as Anti-TNF Drugs
Current Medicinal Chemistry The NMDA Receptor as a Therapeutic Target in Major Depressive Disorder
CNS & Neurological Disorders - Drug Targets Editorial (Thematic Issue: Neurobiological and Neurocognitive Basis of the Effects of Cannabinoids in Animals and Man: Therapeutic Potential of Cannabinoids in Psychiatry)
Current Pharmaceutical Design Health Service Utilization and Costs of Depressive Symptoms in Late Life - A Systematic Review
Current Pharmaceutical Design